- Home
- MATX vs ADPT Comparison
MATX vs ADPT Comparison
Compare MATX & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MATX
- ADPT
- Stock Information
- Founded
- MATX 1882
- ADPT 2009
- Country
- MATX United States
- ADPT United States
- Employees
- MATX N/A
- ADPT N/A
- Industry
- MATX Marine Transportation
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MATX Consumer Discretionary
- ADPT Health Care
- Exchange
- MATX Nasdaq
- ADPT Nasdaq
- Market Cap
- MATX 3.1B
- ADPT 2.6B
- IPO Year
- MATX N/A
- ADPT 2019
- Fundamental
- Price
- MATX $106.61
- ADPT $20.05
- Analyst Decision
- MATX Buy
- ADPT Strong Buy
- Analyst Count
- MATX 5
- ADPT 10
- Target Price
- MATX $143.40
- ADPT $16.60
- AVG Volume (30 Days)
- MATX 393.9K
- ADPT 2.1M
- Earning Date
- MATX 11-04-2025
- ADPT 11-05-2025
- Dividend Yield
- MATX 1.37%
- ADPT N/A
- EPS Growth
- MATX 10.58
- ADPT N/A
- EPS
- MATX 13.11
- ADPT N/A
- Revenue
- MATX $3,382,900,000.00
- ADPT $252,754,000.00
- Revenue This Year
- MATX N/A
- ADPT $36.43
- Revenue Next Year
- MATX $1.45
- ADPT $12.31
- P/E Ratio
- MATX $8.03
- ADPT N/A
- Revenue Growth
- MATX 1.88
- ADPT 42.57
- 52 Week Low
- MATX $86.97
- ADPT $4.27
- 52 Week High
- MATX $158.16
- ADPT $18.98
- Technical
- Relative Strength Index (RSI)
- MATX 56.20
- ADPT 72.63
- Support Level
- MATX $101.98
- ADPT $13.28
- Resistance Level
- MATX $107.74
- ADPT $14.24
- Average True Range (ATR)
- MATX 4.07
- ADPT 1.16
- MACD
- MATX -0.26
- ADPT 0.40
- Stochastic Oscillator
- MATX 36.77
- ADPT 97.11
About MATX Matson Inc.
Matson Inc is engaged in providing ocean transportation and logistics services. The business segments of the company are Ocean Transportation which provides ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, California, Okinawa, and different islands in the South Pacific, and Logistics segment which offers long haul and regional highway trucking services, warehousing and distribution services, supply chain management, and freight forwarding services. The firm generates the majority of its revenue from the Ocean Transportation segment.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).